James R. Tobin - 15 Sep 2026 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Reporting relationship: Director
Issuer ticker: GMED
Reported as of: 15 Sep 2026
Net transaction value: -$2,237,502
SEC form: 4
Accepted by SEC: 16 Sep 2026, 16:35:39 UTC
Prior SEC filing: 17 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly G. Huller, Attorney-in-Fact

Key filing fact

James R. Tobin filed Form 4 for GLOBUS MEDICAL INC (GMED) on 16 Sep 2026.

Key facts

This page summarizes James R. Tobin's Form 4 filing for GLOBUS MEDICAL INC (GMED).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 16:35.

Change

Previous filing in this sequence was filed on 17 Aug 2026.
Current net transaction value: -$2,237,502.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001190128 Primary reporting owner

TOBIN JAMES R

Relationship: Director
Address: VALLEY FORGE BUSINESS CENTER, 2560 GENERAL ARMISTEAD AVENUE, AUDUBON
Signature: /s/ Kelly G. Huller, Attorney-in-Fact
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GMED transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +15,000
Change %
Price: $53.75^*
Shares after: 15,000
Date: 15 Sep 2026
Ownership: Direct

GMED transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +15,000
Change %: +100%
Price: $63.68^*
Shares after: 30,000
Date: 15 Sep 2026
Ownership: Direct

GMED transaction

Class A Common Stock

Sale

Transaction value: $2,237,502
Shares: -30,000
Change %: -100%
Price: $74.58
Shares after: 0
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GMED transaction Derivative

Stock Option (Right to Buy Class A Common Stock)

Options Exercise

Transaction value
Shares: -15,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 15,000
Exercise price: $53.75
Footnotes: F2

GMED transaction Derivative

Stock Option (Right to Buy Class A Common Stock)

Options Exercise

Transaction value
Shares: -15,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 15,000
Exercise price: $63.68
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

Footnote F2

These options were granted on January 26, 2024 and are fully vested.

Footnote F3

These options were granted on January 27, 2022 and are fully vested.